RefuelBio ApS
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
CVR 44 96 09 07AnpartsselskabFrederiksbergStiftet 2024
Bio ApS’ primary activity consists of early-stage research and development of a novel medical drug candidate aimed at preventing muscle loss. The Company focuses on conditions where weight loss is accompanied by muscle loss, including obesity, type 2 diabetes, and other related medical indications.
Oplysningerne er hentet 3. november 2026.